We are the Peptide Experts
JPT Peptide Technologies is the leading manufacturer of custom peptides and innovative peptide-based products for research and clinical applications. For more than 15 years we have been serving the worldwide biomedical community with science and quality driven products and services.
Located in our state-of-the-art laboratories in Berlin, Germany, JPT operates according to the most recent ISO 9001:2015 regulations.
Our Quality Guarantee
Since 2004 JPT maintains an active quality management system that is annually reviewed, audited and certified by an independent certifcation body (TÜV Rheinland) to meet ISO 9001 standards. Therefore, we have installed complete process documentation and an early signaling procedure in case of problems.
Product Finder
Research Fields
NOW available: High purity SARS2 Omicron BA.4/BA.5 PepMixes
After the previous launch of our PepMix peptide pools covering SARS-CoV-2 Omicron BA.4/BA.5 Spike antigens, we now add the >70% purified versions to our catalog. Please note that we at JPT analyze and purify each individual peptide in our 70% PepMixes and assure to provide complete coverage of each antigen:
- PepMix SARS-CoV-2 (Spike / BA.4/BA.5 / Omicron)
- PepMix SARS-CoV-2 (S-RBD / BA.4/BA.5 / Omicron)
ESGCT: Our extensive Peptide Ressources for Gene Therapy
Adenoviruses and Adeno-associated viruses can be used as powerful gene delivery vehicles for the development of vaccines and gene therapy to treat conditions for instance cystic fibrosis, immunodeficiencies (X-SCID), and hematological disorders such as haemophilia and thalassemia. These tools facilitate to detect and monitor the anti-vector T and B-cells' immune response.
NEW: PepMix Pools covering Conserved & Saisonal Influenza A & B Antigens
Based on recommendations, we added selected PepMix peptide pools covering antigens for hemagglutinin (HA) of the following Influenza A & B strains:
- PepMix Influenza A (HA/H3N2/Darwin/2021)
- PepMix Influenza A (HA/H1N1/Victoria/2019)
- PepMix Influenza A (HA/H1N1/Wisconsin/2019)